US Afinion Agreement with MinuteClinic (2124R)

TIDMASD

RNS Number : 2124R

Axis-Shield PLC

01 November 2011

AXIS-SHIELD PLC

AXIS-SHIELD PARTNERS WITH LARGEST U.S. RETAIL MEDICAL CLINIC TO PROVIDE AFINION(TM) SYSTEMS FOR DIABETES MANAGEMENT

CVS Caremark's MinuteClinic selects Afinion(TM) for haemoglobin A1c testing

Dundee, Scotland, 1 November 2011. Axis-Shield plc (LSE:ASD, OSE:ASD) ("Axis-Shield" or the "Company"), the international and innovative in vitro diagnostics company, today announces that it has signed a new agreement with MinuteClinic, the largest retail medical clinic provider in the United States. Under the terms of the agreement, Axis-Shield will provide an Afinion(TM) analyser for each of the approximately 600 MinuteClinic locations in the U.S. so patients can access haemoglobin A1c testing, with results provided in three minutes.

MinuteClinic is a division of CVS Caremark, the largest pharmacy health care provider in the United States. MinuteClinic's walk-in medical clinics are staffed by nurse practitioners and physician assistants, who provide treatment for common family illnesses and injuries, administer vaccinations, conduct physicals and wellness screenings, and offer monitoring for chronic conditions such as diabetes, high cholesterol, high blood pressure and asthma.

Ian Gilham, Chief Executive Officer of Axis-Shield, commented: "We are pleased to be partnering with the largest provider of walk-in medical clinics to bring the simplicity and reliability of Afinion(TM) directly to patients, enabling widespread access to routine haemoglobin A1c testing."

-Ends-

For further enquiries, please contact:

 
 Axis-Shield plc 
 Ian Gilham, Chief Executive Officer                        Tel: +44 203 178 7849 
  Ronny Hermansen, Finance Director 
 
  M:Communications 
 Peter Laing / Emma Thompson /                              Tel: +44 207 920 2330 
  Claire Dickinson                               E-mail: axisshield@mcomgroup.com 
 Corporate Communications (Norway) 
 Geir Bjorlo / Hakon Ronning                                    Tel: +47 23 89 89 
                                                                               30

Notes for Editors

About Axis-Shield

Headquartered in Dundee with R&D and manufacturing facilities in Dundee and Oslo, Axis-Shield is a leading international and innovative company operating in faster growing segments of the in vitro diagnostics (IVD) market. Axis-Shield provides point-of-care testing via its Afinion(TM) and NycoCard(R) instruments and also serves the clinical laboratory through the development of novel tests, particularly for the high throughput analysers of blue-chip original equipment manufacturers (OEMs). The Company has a strong franchise in the diabetes testing market and is developing a cholesterol/lipid panel for testing at the point-of-care, both major areas for future growth. Through its Direct Distribution division, Axis-Shield also markets its own and other third-party products including medical devices to end users in key markets including the USA, Germany, Switzerland, the UK and the Nordic region. For more information on Axis-Shield, please refer to www.axis-shield.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCFDFEFFFFSEES

Axis-shield (LSE:ASD)
Historical Stock Chart
From Oct 2024 to Nov 2024